Crossmark

Safety and efficacy of GLP-1 and glucagon receptor dual agonist for the treatment of type 2 diabetes and obesity: a systematic review and meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s12020-024-03857-6

Published Online: 2024-05-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Deng, Bixin

Ruan, Tiechao

Lu, Wenting

Ying, Junjie

Li, Shiping

Zhou, Ruixi

Mu, Dezhi
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82201905)

National Natural Science Foundation of China (81971433)

Clinical research Special Fund of Wu Jieping Medical Foundation (320.6750.2023-24-4)

National Key R&D Program of China (2021YFC2701700)

Fundamental Research Funds for Central Universities of the Central South University (SCU2023D006)
License Information

Text and Data Mining valid from 2024-05-13

Version of Record valid from 2024-05-13
More Information

Article History

Received: 21 March 2024

Accepted: 29 April 2024

First Online: 13 May 2024

Compliance with ethical standards

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below